Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8484102rdf:typepubmed:Citationlld:pubmed
pubmed-article:8484102lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:8484102lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:8484102lifeskim:mentionsumls-concept:C0021745lld:lifeskim
pubmed-article:8484102lifeskim:mentionsumls-concept:C0034819lld:lifeskim
pubmed-article:8484102lifeskim:mentionsumls-concept:C0041221lld:lifeskim
pubmed-article:8484102lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:8484102lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:8484102pubmed:issue5lld:pubmed
pubmed-article:8484102pubmed:dateCreated1993-5-28lld:pubmed
pubmed-article:8484102pubmed:abstractTextWe have studied the expression of IFN-gamma, IL-2 and IL-2 receptor (IL-2R) at the mRNA and protein levels in spleen and lymph node cells from Trypanosoma cruzi-infected BALB/c mice. At 21 days post infection (dpi) (peak of parasitaemia), spleen cells stimulated with Con A for 16 h showed a reduced IFN-gamma, IL-2 and IL-2R mRNA production compared with non-infected controls. Lymph node cells obtained at 4, 21 or 60 dpi produced similar amounts of IFN-gamma, IL-2 or IL-2R transcripts after mitogen stimulation as uninfected controls. Spleen cells obtained at 21 dpi showed a lower Con A proliferative response and IL-2R expression compared with non-infected controls, while the proliferation and IL-2R expression of lymph node cells at 21 dpi was unaltered. Supernatants from 48 h Con A-stimulated spleen and lymph node cells from mice at 21 dpi had very low levels of IL-2 but contained significantly higher levels of IFN-gamma compared with the supernatants of cells from non-infected mice. The latter phenomenon correlates with an accelerated rate of IFN-gamma mRNA accumulation.lld:pubmed
pubmed-article:8484102pubmed:languageenglld:pubmed
pubmed-article:8484102pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8484102pubmed:citationSubsetIMlld:pubmed
pubmed-article:8484102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8484102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8484102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8484102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8484102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8484102pubmed:statusMEDLINElld:pubmed
pubmed-article:8484102pubmed:monthMaylld:pubmed
pubmed-article:8484102pubmed:issn0300-9475lld:pubmed
pubmed-article:8484102pubmed:authorpubmed-author:OrrEElld:pubmed
pubmed-article:8484102pubmed:authorpubmed-author:RottenbergM...lld:pubmed
pubmed-article:8484102pubmed:authorpubmed-author:LeanderssonTTlld:pubmed
pubmed-article:8484102pubmed:authorpubmed-author:SunnemarkDDlld:pubmed
pubmed-article:8484102pubmed:issnTypePrintlld:pubmed
pubmed-article:8484102pubmed:volume37lld:pubmed
pubmed-article:8484102pubmed:ownerNLMlld:pubmed
pubmed-article:8484102pubmed:authorsCompleteYlld:pubmed
pubmed-article:8484102pubmed:pagination559-68lld:pubmed
pubmed-article:8484102pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:meshHeadingpubmed-meshheading:8484102-...lld:pubmed
pubmed-article:8484102pubmed:year1993lld:pubmed
pubmed-article:8484102pubmed:articleTitleOrgan-specific regulation of interferon-gamma, interleukin-2 and interleukin-2 receptor during murine infection with Trypanosoma cruzi.lld:pubmed
pubmed-article:8484102pubmed:affiliationDepartment of Immunology, Karolinska Institute, Stockholm, Sweden.lld:pubmed
pubmed-article:8484102pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8484102pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8484102pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8484102lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8484102lld:pubmed